 Neuroblastoma
"Neuroblastoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
| Descriptor ID |
D009447
|
| MeSH Number(s) |
C04.557.465.625.600.590.650.550 C04.557.470.670.590.650.550 C04.557.580.625.600.590.650.550
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neuroblastoma".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Neoplasms, Germ Cell and Embryonal [C04.557.465]
- Neuroectodermal Tumors [C04.557.465.625]
- Neoplasms, Neuroepithelial [C04.557.465.625.600]
- Neuroectodermal Tumors, Primitive [C04.557.465.625.600.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.465.625.600.590.650]
- Neuroblastoma [C04.557.465.625.600.590.650.550]
- Neoplasms, Glandular and Epithelial [C04.557.470]
- Neoplasms, Neuroepithelial [C04.557.470.670]
- Neuroectodermal Tumors, Primitive [C04.557.470.670.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.470.670.590.650]
- Neuroblastoma [C04.557.470.670.590.650.550]
- Neoplasms, Nerve Tissue [C04.557.580]
- Neuroectodermal Tumors [C04.557.580.625]
- Neoplasms, Neuroepithelial [C04.557.580.625.600]
- Neuroectodermal Tumors, Primitive [C04.557.580.625.600.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.580.625.600.590.650]
- Neuroblastoma [C04.557.580.625.600.590.650.550]
Below are MeSH descriptors whose meaning is more specific than "Neuroblastoma".
This graph shows the total number of publications written about "Neuroblastoma" by people in this website by year, and whether "Neuroblastoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 1 | 2 | 3 | | 1982 | 1 | 1 | 2 | | 1983 | 0 | 1 | 1 | | 1984 | 2 | 1 | 3 | | 1985 | 1 | 0 | 1 | | 1986 | 2 | 1 | 3 | | 1989 | 3 | 1 | 4 | | 1990 | 0 | 3 | 3 | | 1991 | 3 | 4 | 7 | | 1992 | 1 | 2 | 3 | | 1993 | 1 | 1 | 2 | | 1994 | 0 | 3 | 3 | | 1995 | 1 | 3 | 4 | | 1996 | 1 | 6 | 7 | | 1997 | 1 | 4 | 5 | | 1998 | 1 | 4 | 5 | | 1999 | 1 | 2 | 3 | | 2000 | 2 | 5 | 7 | | 2001 | 1 | 1 | 2 | | 2002 | 5 | 1 | 6 | | 2003 | 5 | 1 | 6 | | 2004 | 3 | 1 | 4 | | 2005 | 4 | 2 | 6 | | 2006 | 1 | 3 | 4 | | 2007 | 4 | 1 | 5 | | 2008 | 1 | 1 | 2 | | 2009 | 7 | 0 | 7 | | 2010 | 9 | 0 | 9 | | 2011 | 11 | 1 | 12 | | 2012 | 14 | 0 | 14 | | 2013 | 12 | 0 | 12 | | 2014 | 10 | 1 | 11 | | 2015 | 8 | 2 | 10 | | 2016 | 12 | 0 | 12 | | 2017 | 10 | 1 | 11 | | 2018 | 5 | 0 | 5 | | 2019 | 6 | 0 | 6 | | 2020 | 8 | 2 | 10 | | 2021 | 9 | 1 | 10 | | 2022 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Neuroblastoma" by people in Profiles.
-
Cohn SL, Pearson ADJ. Rethinking high-risk neuroblastoma treatment. Pediatr Blood Cancer. 2022 Aug; 69(8):e29730.
-
DuBois SG, Macy ME, Henderson TO. High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-13.
-
Mayampurath A, Ramesh S, Michael D, Liu L, Feinberg N, Granger M, Naranjo A, Cohn SL, Volchenboum SL, Applebaum MA. Predicting Response to Chemotherapy in Patients With Newly Diagnosed High-Risk Neuroblastoma: A Report From the International Neuroblastoma Risk Group. JCO Clin Cancer Inform. 2021 12; 5:1181-1188.
-
Pan M, Wright WC, Chapple RH, Zubair A, Sandhu M, Batchelder JE, Huddle BC, Low J, Blankenship KB, Wang Y, Gordon B, Archer P, Brady SW, Natarajan S, Posgai MJ, Schuetz J, Miller D, Kalathur R, Chen S, Connelly JP, Babu MM, Dyer MA, Pruett-Miller SM, Freeman BB, Chen T, Godley LA, Blanchard SC, Stewart E, Easton J, Geeleher P. The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. Nat Commun. 2021 11 09; 12(1):6468.
-
Kawano A, Hazard FK, Chiu B, Naranjo A, LaBarre B, London WB, Hogarty MD, Cohn SL, Maris JM, Park JR, Gastier-Foster JM, Ikegaki N, Shimada H. Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group. Am J Surg Pathol. 2021 08 01; 45(8):1075-1081.
-
Irwin MS, Naranjo A, Zhang FF, Cohn SL, London WB, Gastier-Foster JM, Ramirez NC, Pfau R, Reshmi S, Wagner E, Nuchtern J, Asgharzadeh S, Shimada H, Maris JM, Bagatell R, Park JR, Hogarty MD. Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. J Clin Oncol. 2021 10 10; 39(29):3229-3241.
-
DuBois SG, Granger MM, Groshen S, Tsao-Wei D, Ji L, Shamirian A, Czarnecki S, Goodarzian F, Berkovich R, Shimada H, Villablanca JG, Vo KT, Pinto N, Mosse YP, Maris JM, Shusterman S, Cohn SL, Goldsmith KC, Weiss B, Yanik GA, Twist CJ, Irwin MS, Haas-Kogan DA, Park JR, Marachelian A, Matthay KK. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. J Clin Oncol. 2021 11 01; 39(31):3506-3514.
-
Balyasny S, Lee SM, Desai AV, Volchenboum SL, Naranjo A, Park JR, London WB, Cohn SL, Applebaum MA. Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma. JAMA Netw Open. 2021 07 01; 4(7):e2116248.
-
Bao R, Spranger S, Hernandez K, Zha Y, Pytel P, Luke JJ, Gajewski TF, Volchenboum SL, Cohn SL, Desai AV. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. J Immunother Cancer. 2021 07; 9(7).
-
Bona K, Li Y, Winestone LE, Getz KD, Huang YS, Fisher BT, Desai AV, Richardson T, Hall M, Naranjo A, Henderson TO, Aplenc R, Bagatell R. Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma. J Natl Cancer Inst. 2021 03 01; 113(3):282-291.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|